MIJ invests in Blueberry Therapeutics Ltd.
MIJ is pleased to announce that we have recently invested in “Blueberry Therapeutics Ltd.”, a British life science start-up that has developed its own unique nano-formulation technology. Although many therapeutic drugs for treating skin conditions exist, until now there have been issues regarding the subcutaneous penetration of active ingredients. Blueberry Therapeutics’ “nano-formulation technology” has brought about a breakthrough that is expected to resolve these issues. The company is currently pursuing development of this technology as a means of treating onychomycosis (fungal nail), a common disease, and high expectations are held that in future it will be possible to apply this therapy to a broad array of illnesses and conditions such as acne and atopic dermatitis.
- 18/06/2021MIJ invests in Heartseed Inc.
- 29/01/2021Blueberry Therapeutics announces extension of its Series B round with investment from Medical Incubator Japan and US Dermatology Syndicate
- 15/01/2021MIJ invests in Blueberry Therapeutics Ltd.
- 01/12/2020UK biotech company ILC Therapeutics announces first international investment